4D Molecular Therapeutics Accelerates Phase 3 Trial for 4D-150 in Wet AMD with Early Initiation of 4FRONT-2
I'm PortAI, I can summarize articles.
4D Molecular Therapeutics Inc. has accelerated its Phase 3 clinical program for 4D-150, a treatment for Wet AMD, with topline data expected in early 2027. The initiation of the 4FRONT-2 trial has also been expedited. This follows positive results from the SPECTRA trial in Diabetic Macular Edema, showing good tolerability and durability. To enhance efficiency, the company has reduced its workforce by 25%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments